drugset / Trial / NCT01402037

Beta Cell Function in (Pre)Type 1 Diabetes

NCT01402037

Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

Increased glycemic variability has been proposed as an independent predictor of hypoglycemia in diabetic patients. Likewise, episodes of dysglycemia have been found to be predictive of diabetes in antibodypositive nondiabetic individuals. We hypothesise that an in-depth observational study comparing state-of-the-art measures of functional beta cell mass and glycemic variability will specify the relationship between both variables over a broad range of residual function and will identify treatment goals for functional beta cell mass to be reached in future beta cell therapy trials in order to avoid frequent hypoglycemia in patients and dysglycemia in risk groups. The available expertise and infrastructure (see background and (inter)national context) place the promoters of the present project in a unique position to carry out the planned experiments and support their feasibility.

Timeline

Start
2011-07
Primary completion
2015-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Background Glucose Unknown 20 % Intravenous